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TBBPA is a non-genotoxic ﬂame retardant used to improve ﬁre safety in a wide variety of consumer
products. Estimated human exposures to TBBPA are very low (<0.000084 mg/kg-day), relative to the
doses (500 and 1000 mg/kg-day of TBBPA) administered in a recent bioassay that resulted in uterine
tumors in Wistar Han rats following chronic exposure. As part of an effort to characterize the relevance of
the uterine tumors to humans, data and biological knowledge relevant to the progression of events
associated with TBBPA-induced uterine tumors in female rats were organized in an adverse outcome
pathway (AOP) framework. Based on a review of possible MOAs for chemically induced uterine tumors
and available TBBPA data sets, a plausible molecular initiating event (MIE) was the ability of TBBPA to
bind to and inhibit estrogen sulfotransferases, the enzymes responsible for sulfation of estradiol. Sub-
sequent key events in the AOP, including increased bioavailability of unconjugated estrogens in uterine
tissue, would occur as a result of decreased sulfation, leading to a disruption in estrogen homeostasis,
increased expression of estrogen responsive genes, cell proliferation, and hyperplasia. Available data
support subsequent key events, including generation of reactive quinones from the metabolism of es-
trogens, followed by DNA damage that could contribute to the development of uterine tumors. Un-
certainties associated with human relevance are highlighted by potential strain/species sensitivities to
development of uterine tumors, as well as the characterization of a dose-dependent MIE. For the latter, it
was determined that the TBBPA metabolic proﬁle is altered at high doses (such as those used in the
cancer bioassay), and thus an MIE that is only operative under repeated high dose, administration. The
MIE and subsequent key events for the development of TBBPA-induced uterine tumors are not feasible in
humans given differences in the kinetic and dynamic factors associated with high dose exposures in rats
relative to human exposure levels to TBBPA.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Adverse outcome pathways (or AOPs) are a tool for organizing
data in a framework of knowledge concerning the progression of
key events across scales of biological organization that lead to
adverse outcomes relevant for human risk assessment (OECD,
2013). In the case of carcinogens, such organization aids in the
characterization of possible modes of action (MoA) associated with
development of an adverse outcome, as well as potential extrapo-
lation of such to populations. An AOP typically involves a molecular, TX 78759, United States.
ikoff).
Inc. This is an open access article uinitiating event (MIE), which is an initial interaction between a
foreign molecule and a biomolecule that can be linked via key
events to an adverse outcome (Allen et al., 2014). The process of
deﬁning an AOP can be used to identify data gaps for testing the
feasibility of a MoA, to assist in developing and/or interpreting the
predictability of in vitro assays, as well as to integrate these ap-
proaches in the practice of hazard identiﬁcation and risk
assessment.
While AOPs are not unique to a chemical, evaluation of re-
sponses associated with exposures to a speciﬁc chemical can aid in
the elucidation of an AOP. In this study, we present an AOP for
uterine tumors in Wistar Han rats and use data available for
tetrabromobisphenol-A (TBBPA), a non-genotoxic ﬂame retardantnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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A relatively recent study conducted by National Toxicology Pro-
gram (NTP) reported that chronic administration of TBBPA at doses
of 500 and 1000 mg/kg-day resulted in uterine tumors in female
rats (NTP, 2014). This compound was selected as a case study, as the
data present a unique challenge with respect to characterizing and
extrapolating the uterine tumors observed in rats to potential ef-
fects to humans, as the lowest dose tested by the NTP was
approximately eight orders of magnitude higher than estimates of
human exposure reported in the scientiﬁc literature (EU, 2006;
Health Canada, 2013; EFSA, 2011; Colnot et al., 2014; Wikoff et al.,
2015). This poses challenges when attempting to extrapolate
ﬁndings from these studies to humans, particularly considering
that there are often uncertainties in determining if the adverse
effects observed at high doses may have been a result of perturbed
normal physiological functions and protective mechanisms, other-
wise known as dose dependent transitions in toxicity (Slikker et al.,
2004).
A large number of studies have reported TBBPA in media asso-
ciated with human exposure, including soil, foodstuffs, and to a
lesser extent, water and air (Health Canada, 2013; EU, 2006; Colnot
et al., 2014; Wikoff et al., 2015). Although there is potential for
widespread exposure, measured concentrations of TBBPA in serum
are low in humans (and often below limits of analytical detection)
(Jakobsson et al., 2002; Shi et al., 2013; Sjodin et al., 2003). How-
ever, TBBPA has been detected in human serum samples in both
occupational and non-occupational settings, as well as in breast
milk, demonstrating that the compound is absorbed following
exposure, and that assessment of hazard and risk following expo-
sure may be warranted. Daily estimates of exposure to TBBPA are
relatively consistent. For example, the NTP (2014) reported a hu-
man exposure of 2.6E-6 mg/kg-day, and Wikoff et al. (2015) re-
ported that average daily dose levels are estimated to range from
3.2E-7 to 8.4E-5 mg/kg-day. The European Food Safety Authority
(2011), the European Union (2006), and Health Canada (2013)
have derived similar estimates. These estimates of exposure are
approximately eight orders of magnitude (or more) lower than the
doses used in the carcinogenicity assay, which ranged from250mg/
kg-day to 1000 mg/kg-day.
Given the substantial difference in the levels of TBBPA that
humans are typically exposed to relative to the doses levels used in
the NTP study, it is important to characterize the MoA by which
TBBPA caused uterine tumors at high doses in female Wistar Han
rats in order to extrapolate those ﬁndings for purposes of predicting
potential human risk. This is consistent with guidance from
numerous regulatory agencies, which emphasizes the importance
of characterizing the MoA underlying a carcinogenic response
observed in an experimental study prior to extrapolating ﬁndings
from that study to humans (Boobis et al., 2006; IPCS, 2007; USEPA,
2005). Though potential MoAs associated with the development of
uterine tumors following chronic, high dose exposures to TBBPA
have been discussed (Dunnick et al., 2015; Lai et al., 2015), the data
for uterine tumors have not been critically evaluated in an AOP
framework. As such, the goals of this paper were: 1) to characterize
the MoA for TBBPA induced uterine tumors within an AOP frame-
work, with particular emphasis on identiﬁcation of the MIE, 2) to
demonstrate how theMoA (organized in an AOP framework) can be
used to characterize the plausibility and human relevance of the
adverse outcome, and 3) to identify data gaps and research needs.
Analysis of the MoA for TBBPA in the AOP framework allows for a
systematic approach for determining both the species speciﬁcity of
each event, along with the feasibility of these events occurring
following exposure to relatively low environmental concentrations.2. Approach
A comprehensive literature search was conducted using
PubMed and EMBASE to identify literature associated with the
development of uterine tumors in Wistar Han rats, as well as to
identify literature associated with potential key events related to
carcinogenicity following exposures to TBBPA. Searches were
guided by discussions on potential MoAs both generally for
chemically-induced uterine tumors, as well as those speciﬁc to
TBBPA carcinogenicity, as provided by Lai et al. (2015); Dunnick
et al. (2015), and Klaunig et al. (2015). Relevant studies identiﬁed
in the peer-reviewed literature were critically evaluated using a
weight of evidence approach as appropriate to each topic area. In
addition, primary data from publicly available databases including
the EPA's Endocrine Disruptor Screening Program for the 21st
Century (EDSP21) Dashboard (http://actor.epa.gov/edsp21), the
NTP's Chemical Effects in Biological Systems (CEBS) database
(http://www.niehs.nih.gov/research/resources/databases/cebs/),
the Kyoto Encyclopedia of Genes and Genomes (KEGG) (http://
www.genome.jp/kegg/), and the Comparative Toxicogenomics
Database (CTD) (http://ctdbase.org/) were each independently
assessed. This involved data query and extraction of information
related to the potential for TBBPA to disrupt the estrogen pathway.
Extracted data were summarized in a tabular format using Micro-
soft Excel. Tp53 mutation incidences reported in the NTP TBBPA
cancer bioassay report (NTP, 2014) and the related peer-reviewed
publication (Harvey et al., 2015) were evaluated for statistical sig-
niﬁcance using a one-sided Fisher Exact test (GraphPad Prism v6).
The MIE, as well as other key events, were evaluated in the context
of established regulatory guidelines and/or standard scientiﬁc
practice (Allen et al., 2014; Boobis et al., 2006; USEPA, 2005; IPCS,
2007; Meek et al., 2003, 2014; OECD, 2013).
The results of the assessment are presented in three sections of
this paper. In the ﬁrst section, relevant background information is
provided on TBBPA including: general toxicity, genetic toxicology,
carcinogenicity, and toxicokinetic information. Notably, informa-
tion in this ﬁrst section is not intended as a comprehensive review
of TBBPA toxicity, but rather is focused on key information related
to uterine tumors that is important to understanding the subse-
quent discussions concerning MoA underlying the high dose effects
observed in the NTP study. The second section describes an AOP
framework used to evaluate uterine tumor development as the
adverse outcome. This section includes evaluation of potential
MIEs, and speciﬁcally, a critical assessment of the data available to
characterize each MIE as it relates to exposure to TBBPA. This sec-
tion also identiﬁes themost plausibleMIE and includes a discussion
of subsequent key events and supporting data to anchor the MIE to
the adverse outcome (AO). In the third section, the plausibility and
human relevance of the proposed MoA, in context of the proposed
AOP, are discussed, with particularly focus on concordance between
datasets, species, and the role of kinetic and dynamic factors.
3. Relevant background information on the toxicity of TBBPA
3.1. Toxicities in guideline-based studies
TBBPA is a well-studied compound. Human health risks asso-
ciated with TBBPA exposure have generally been characterized as
low, even when upper bound estimates of exposure are considered
(Colnot et al., 2014; EU, 2006; Health Canada, 2013; Wikoff et al.,
2015). Such evaluations have been based primarily on extrapola-
tions of data from experimental studies in rodents, as toxicity data
in humans are limited. TBBPA has generally been found to have
unremarkable effects when evaluated in several guideline-
compliant toxicity studies, including a 28-day study, multiple 90-
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2008; NTP, 2014; Osimitz et al., 2016), and a two- and a one-
generation reproductive and developmental study (Cope et al.,
2015; van der Ven et al., 2008), involving doses of up to 1000 mg/
kg .3.2. Genetic toxicology
TBBPA has been evaluated within several model systems for its
potential mutagenicity and/or genotoxicity. These data, which are
described below, demonstrate that there is no evidence to suggest
that TBBPA directly induces mutations, DNA damage, or chromo-
somal damage. This conclusion is consistent with those reached by
both the EU (2006) and Health Canada (2013) in the course of their
comprehensive reviews of TBBPA. TBBPA has been evaluated in ten
separate in vitro mutagenicity studies, all of which have yielded
negative ﬁndings. These studies include a number of published
studies (Helleday et al., 1999; Mortelmans et al., 1986; NTP, 2014),
as well as several unpublished studies (EU, 2006). Several of the
these assays involved Ames assays using various strains of Salmo-
nella typhimurium and Escherichia coli and tested negative for
TBBPA-induced mutagenicity at doses up to 10,000 mg/plate (with
and without metabolic activation). Additionally, there were no in-
creases in intragenic recombinations in a study using Chinese
hamster cells exposed to up to 70 mg TBBPA/ml (Helleday et al.,
1999).
TBBPA has also been evaluated for chromosomal aberrations in
human peripheral blood lymphocytes; no evidence of an increase
in either structural or numerical chromosomal aberrations in any of
the treatment groups (BioReliance, 2001 as reported in EU, 2006).
More recently, TBBPA was evaluated for its ability to induce the
formation of micronuclei in male and female B6C3F1/N mice
exposed orally for 3 months to dose levels ranging from 10 to
1000 mg/kg (NTP, 2014). In this study, there was no increase in the
frequency of micronuclei in normochromatic erythrocytes, nor
were there any signiﬁcant changes in the percentage of circulating
polychromatic (immature) erythrocytes and overall, TBBPA did not
induce bone marrow genotoxicity over the dose range tested. Thus,
the negative ﬁndings in the micronucleus assay, as well as other
studies described above, collectively suggest that TBBPA likely acts
through a non-genotoxic MoA.3.3. Carcinogenicity (uterine tumors)
The potential association between TBBPA exposure and cancer
has not been evaluated in humans. In animals, the carcinogenicity
of TBBPA has been evaluated in a cancer bioassay (Dunnick et al.,
2015; NTP, 2014). In this bioassay, TBBPA was administered by
oral gavage to male and female Wistar Han rats [Crl:Wi(Han)] and
B6C3F1/N mice at doses of 0, 250, 500, or 1000 mg/kg for 5 days/
week for 2 years. In female rats, TBBPA exposure resulted in uterine
adenomas, adenocarcinomas, and Mixed Müllerian tumors in the
two highest dose groups (500 and 1000 mg/kg). When assessing
the uterine tissues, NTP ﬁrst reviewed the tissues in transverse
sections, and then later assessed the tissues in longitudinal sections
(Table 1). When combined, ﬁndings from the transverse and lon-
gitudinal reviews showed a statistically signiﬁcant increase in
uterine tumors in the 500 and 1000 mg/kg dose groups relative to
the controls (16/50, 19/50 and 6/50, respectively), as well as a sta-
tistically signiﬁcant doseeresponse trend of the combined tumor
types. These ﬁndings were considered by the NTP to provide clear
evidence of carcinogenic activity of TBBPA in female Wistar Han
rats.3.4. Toxicokinetics
Toxicokinetic data for TBBPA include investigations in multiple
species following exposure via various routes and durations, and
include characterization of its major metabolites. TBBPA has been
found to be rapidly absorbed following oral exposure in humans
and rodents and is then rapidly metabolized and excreted in the
feces and urine. Estimated half-lives are ~2 days and <5 h in
humans and rats (EU, 2006; Schauer et al., 2006), respectively;
therefore providing evidence of limited tissue retention especially
in humans.
Many studies have evaluated the toxicokinetics of TBBPA in
rodents, demonstrating that TBBPA is rapidly absorbed and efﬁ-
ciently metabolized by glucuronyltransferases and sulfo-
transferases in the liver, resulting in low systemic exposure (EU,
2006; Schauer et al., 2006; Kang et al., 2009; Kuester et al., 2007).
These studies are highlighted by ﬁndings reported by Knudsen et al.
(2014) who recently evaluated the disposition and kinetics of
TBBPA in female Crl:WI(Han) rats (the same strain used in the
cancer bioassay) following a single dose of [14C]TBBPA by oral
gavage (25, 250, and 1000 mg/kg) or via IV bolus (25 mg/kg). The
authors also conducted additional investigations at the mid-dose
(250 mg/kg), which included evaluation of biliary excretion
following gavage administration, and assessment of kinetics
following repeated dosing. These authors reported that TBBPA was
rapidly absorbed, with absorption and elimination half-lives esti-
mated to be ~54 and 155 min, respectively. Terminal half-lives of
233 or 133 min were observed following oral or IV administration,
respectively, resulting in an overall systemic bioavailability of less
than 5%, primarily due to a signiﬁcant ﬁrst pass effect. Knudsen
et al. (2014) reported a “signiﬁcant delay” in fecal excretion
within the ﬁrst 24 h was observed in animals from the high dose
group. Repeated exposure did not alter the pattern of distribution
or routes of elimination. Two major metabolites were identiﬁed,
but not quantiﬁed, in the bile of rats orally administered 250 mg/kg
TBBPA: TBBPA-sulfate and TBBPA-glucuronide. Based on the ﬁnd-
ings observed in this study, the authors concluded with respect to
the kinetic behavior of TBBPA in female Wistar Han rats adminis-
tered high doses of TBBPA: “Elimination pathways appeared to
become saturated leading to delayed excretion after a single oral
administration of the highest dose (1000 mg/kg); no such satura-
tion or delay was detected at lower doses.”
The human data are based on a study by Schauer et al. (2006), in
which the authors measured levels of TBBPA and its sulfate and
glucuronide conjugates in blood and urine samples from humans
administered 0.1 mg/kg of TBBPA in a gel capsule. In evaluation of
the proﬁles of TBBPA and its conjugates over time, the authors
suggested a role of polymorphic sulfotransferase activity associated
with TBBPA metabolism, and concluded that TBBPA had a low
systemic bioavailability following oral administration in humans.
4. Proposed AOP for TBBPA-Induced uterine tumors
Chemicals have been shown to induce uterine adenocarcinomas
in rats through both genotoxic and non-genotoxic MoAs. Genotoxic
chemicals can induce uterine adenocarcinomas by an interaction of
reactive/electrophilic metabolites with DNA. Known genotoxic
chemicals such as nitrosamines have been shown to increase the
incidence of uterine tumors in rats (Tanaka and Mori, 1983). Since
the genotoxicity of TBBPA has been evaluated both in vivo and
in vitro with results clearly indicating that the compound is not
directly genotoxic or mutagenic, the focus of this evaluationwill be
on the identiﬁcation of a potential non-genotoxic MoA. More spe-
ciﬁcally, given the nature of the tumor type, the focus will be on
potential non-genotoxic MoAs that involve disruption of estrogen
Table 1
Lesions in uterine tissues of female Wistar Han rats exposed to TBBPA for 2 years (NTP, 2014). All counts are out of 50 total animals per dose group.
Uterus pathology review Dose (mg/kg) Endometrium hyperplasia, cystic Endometrium hyperplasia, atypical Adenoma Adenocarcinomaa MMMT Combinedb
Original transverse 0 (control) 8 (16%) NR 0 (0%)g 3 (6%)e 0 (0%) 3 (6%)g
250 13 (26%) NR 0 (0%) 3 (6%) 4 (8%) 7 (14%)
500 11 (22%) NR 3 (6%) 8 (16%) 0 (0%) 11 (22%)d
1000 18 (36%)d NR 4 (8%) 9 (18%) 2 (4%) 13 (26%)f
Residual longitudinal 0 (control) 23 (46%) 2 (4%) 3 (6%) 4 (8%)g 0 (0%) 6 (12%)g
250 30 (60%) 13 (26%)f 2 (4%) 9 (18%) 0 (0%) 10 (20%)
500 28 (56%) 11 (22%)f 1 (2%) 15 (30%)f 0 (0%) 16 (32%)f
1000 31 (62%) 13 (26%)f 3 (6%) 15 (30%)f 1 (2%) 16 (32%)d
Combinedc 0 (control) 24 (48%) 2 (4%) 3 (6%) 4 (8%)g 0 (0%) 6 (12%)g
250 31 (62%) 13 (26%)f 2 (4%) 10 (20%) 4 (8%) 11 (22%)
500 30 (60%) 11 (22%)f 4 (8%) 15 (30%)f 0 (0%) 16 (32%)f
1000 32 (64%) 13 (26%)f 6 (12%) 16 (32%)f 2 (4%) 19 (38%)f
MMMT, malignant mixed Müllerian tumor.
NR, not reported.
a Includes multiple adenocarcinomas.
b Adenoma, Adenocarcinoma, and/or MMMT.
c Original transverse and/or residual longitudinal.
d p  0.05 as calculated by the poly-3 pairwise (dose versus control) tests.
e p  0.05 as calculated by the poly-3 trend tests across all dose groups.
f p  0.01 as calculated by the poly-3 pairwise (dose versus control) tests.
g p  0.01 as calculated by the poly-3 trend tests across all dose groups.
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identiﬁed by Klaunig et al. (2015) to do so through one of three
general mechanisms: a) direct binding and activation of estrogen
receptors (ER), b) binding and activation of dopamine receptor
agonist, or c) disruption of estrogen metabolism.
As reviewed by Rizner (2013), data in the literature supports the
action of estrogens as both a tumor initiator and promoter. With
increased estrogen bioavailability in estrogen sensitive tissues such
as the endometrium, there is an increase in estrogen binding to the
ER, as well as its being metabolized by CYP1B1 (cytochrome P450,
family 1, subfamily B, polypeptide 1) to genotoxic 4-hydroxy-es-
trogens. The 4-hydroxy-estrogens in turn form 3,4 quinones, which
are reactive oxygen species, and DNA adducts at apurinic sites.
These DNA adducts, if unrepaired, may lead to the induction of DNA
mutations in cancer-related genes, including tumor suppressors
and oncogenes. With binding of estrogens to the ER, there is
expression of estrogen target genes leading to enhanced prolifer-
ation of previously transformed cells causing additional errors in
replication and potential further DNA mutations. The initiation of
cancer, as a result of an imbalance of estrogenmetabolism, has been
reviewed by Cavalieri and Rogan (2014). These authors concluded
that kidney cancer in male Syrian hamsters, prostate cancer in
Nobel rats, and breast cancer in women occurs via this mechanism.
Dunnick et al. (2015), and more recently Lai et al. (2015), hy-
pothesized that the MoA for TBBPA-induced uterine tumors in-
volves disruption of estrogen homeostasis through its ability to
inhibit estrogen conjugation. This event(s) results in decreased
elimination and increased estrogen activity or generation of es-
trogen metabolites, which can also potentially act as mutagenic
carcinogens (Yager and Liehr, 1996). Although these previous
publications have discussed potential MoA's for TBBPA-induced
uterine tumors, a comprehensive effort to compile and present
underlying data in an AOP framework has not yet been reported in
the literature e an issue recently highlighted by the USEPA (2005).
As such, in the discussion that follows, we provide a data-driven
evaluation of the MoA (IPCS, 2007; USEPA, 2005) in the frame-
work of an AOP, with particular focus on characterizing the MIE.
More speciﬁcally, we evaluate each potential pathway (e.g., ER
agonist, dopamine receptor agonist, and disruption of estrogen
metabolism) associated with potential disruption in the homeo-
stasis of estrogens in the uterus. Each potential pathway is dis-
cussed in the context of available data on TBBPA, as well as in thecontext of considerations for non-chemical speciﬁc data linking the
potential MIE to the adverse outcome (AO).
4.1. Potential MIEs
4.1.1. Estrogen receptor (ER) agonist
Estrogens stimulate cell proliferation through binding and
activation of the estrogen receptors, ERa and ERb, which are
encoded by the ESR1 and ESR2 genes, respectively. Once activated
by estrogens, these ERs can act as transcription factors regulating
the transcription of genes involved in cell cycle and cell prolifera-
tion, thus leading to increased risk of genomic mutations during
DNA replication (reviewed by Rizner, 2013). Direct binding to and
activation of estrogen receptors is the most prominent mechanism
involved in disruption of estrogen homeostasis. This mechanism
has been well studied, and is highlighted by the extensive research
on tamoxifen, which is a direct ERa agonist in endometrial tissue
(IARC, 2012). In both rats and humans, prolonged administration of
tamoxifen is associated with the development of uterine adeno-
carcinomas (IARC, 2012). The potential for TBBPA to be an ER
agonist has been evaluated in an array of in vitro assays in bacterial,
mammalian, and human cells across 15 different assays (see Table 2
for references). The active assays showing weak positive activity
include the following: 1) a recombinant yeast transcription assay in
which the activity was determined only at the highest TBBPA
concentration, 2) 1 out of 2 estrogen luciferase reporter assays in
the MCF-7 human breast cancer cell line, 3) 1 out of 3 E-screen
assays for proliferation, and 4) an estrogen luciferase reporter assay
that did not provide an adequate doseeresponse curve to calculate
effective concentrations (K€orner et al., 1998; Kitamura et al., 2005;
Li et al., 2010; Suzuki et al., 2013) (Table 2).
As part of a further evaluation of this MIE, high throughput
screening (HTS) data reported by ToxCast™ and Tox21 within the
EDSP21 dashboard (http://actor.epa.gov/edsp21/) were obtained
and reviewed as a part of this assessment. The 16 HTS assays
available for both ERa and ERb agonist activity include: 3 cell-free
radio-ligand binding assays, 6 protein complementation assays
measuring formation of dimers and testing for activity against ERa
and ERb, 2 assaysmeasuring interaction of themature transcription
factor with DNA, 2 reporter gene assays measuring mRNA tran-
script levels, 2 assays measuring reporter protein level readouts,
and 1 ER-sensitive cell proliferation assay. TBBPA was found to be
Table 2
Lines of evidence from the published literature characterizing TBBPA ER bioactivity.
Reference Assay(s) Endpoints Result
Dorosh
et al.,
2011
E-Screen bioassay and qRT-PCR with MCF-7 human breast
cancer cell line
MTT proliferation and estrogen-responsive TFFI
expression
Negative
Hamers
et al.,
2006
ER-CALUX using T47D human breast cancer cell line ER activation measured using luciferase activity Negative
K€orner
et al.,
1998
E-Screen bioassay with MCF-7 human breast cancer cell line Relative potency with estradiol equivalency
factor (EEF) measured using MTT cell
proliferation
Positive; relative potency EEF was
5  106 compared to 1 for 17b-estradiol
Kitamura
et al.,
2005
Estrogen Luciferase Reporter Assay using MCF-7 human breast
cancer cell line
ER activation measured using luciferase activity Positive, weak; EC50 (in mM) of 19
compared to 8.6  106 for estradiol and
0.63 for BPA
Li et al.,
2010
Recombinant yeast assay on ER mediated transcription (yeast
two-hybrid assay, ERa-Laz)
ER activation measured using b-galactosidase
activity
Positive, weak; only at the highest
concentration tested without cytotoxicity,
with REC20> 1  105 mol/L
Lee et al.,
2012
OECD test guideline 455; stably transfected transcriptional
activation (STTA) and estrogen binding assays using hERa-HeLa-
9903 cell line
ER activation measured using luciferase activity Negative
Meerts
et al.,
2001
ER-CALUX assay using T47D breast cancer cell line ER activation measured using luciferase activity Negative
Miller
et al.,
2001
Recombinant yeast estrogen assay transfected with hERa and
expression plasmids (containing estrogen response elements
and lac-Z reporter gene)
ER activation measured using b-galactosidase
expression
Negative
Molina-
Molina
et al.,
2013
1. Stably transfected luciferase reporters hERaERStahERb using
MELN with MCF-7 cell lines
2. E-Screen bioassay with MCF-7 cell line
1. ER activation measured using luciferase
activity
2. MTT cell proliferation
1. Negative
2. Negative
Riu et al.,
2011a
1. Stably transfected reporter cell lines HGELN-ERa and HGELN-
ERb
2. ER NR-based afﬁnity columns
1. ERa and ERb activation measured using
luciferase activity
2. ER NR binding afﬁnity measured using
radioactivity
1. Negative
2. Negative
Riu et al.,
2011b
Stably transfected reporter cell lines HGELN-ERa and HGELN-
ERb
ERa and ERb activation measured using
luciferase activity
Low activity
Suzuki
et al.,
2013
ER-CALUX assay using human osteosarcoma cells ER activation measured using luciferase activity Positive, weak; REC5 was 1  105 and
EC50 value was not calculated due to lack
of complete doseeresponse curve
Zhuang
et al.,
2014
Modeling of molecular recognition sites of TBBPA to ERa Physicochemical properties, construction of
protein-ligand structures, binding free energy
involved in computational simulations
Negative; No hydrogen bonds formedwith
ERa ligand binding domain
CALUX, chemically activated luciferase gene expression.
EC50, median effective concentration.
EEF, estradiol equivalency factor.
MTT, 3-(4,5-dimethyl thiazolyl-2) 2,5-diphenyltetrazolium bromide.
qRT-PCR, reverse transcription quantitative polymerase chain reaction.
REC5, 5% relative effective concentration.
REC20, 20% relative effective concentration.
TFF1, trefoil factor 1.
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50% maximal assay activity was achieved (AC50) ranged from 4.85
to 33.80 mM (Table 4). For comparison, the natural phytoestrogen
genistein was active in 16 of 16 ER agonist assays and tamoxifen
was positive in 13 of 16 agonist assays with the majority of AC50
values being <1 mM (Tables 3 and 4).
The results from these ER-related assays were modeled to
determine the overall weight of evidence for determining the ER
activity as represented by an AUC value deﬁned by Judson et al.
(2015). The AUC value is an integration of the activity among the
16 assays which results in a value ranging from 0 to 1 for agonist
activity (e.g., 17a-Ethinylestradiol has an AUC agonist value of 1). As
reported within the EDSP21 dashboard, TBBPA was modeled to
have an AUC value of 0 for ER agonist activity, and thus is given an
overall designation of being inactive for ER (Table 4). For compar-
ison, the AUC value reported for genistein, a compound considered
to be an active ER agonist (Judson et al., 2015), is 0.538.
The results from the ToxCast™/Tox21 assays, along with the
weak and/or negative results in the peer-reviewed literature
described above, together provide strong evidence that TBBPA isnot an ER agonist. As such, direct interaction with ER is not a
feasibleMIE associatedwith TBBPA-induced alternation in estrogen
homeostasis.
4.1.2. Dopamine receptor agonists and prolactin regulation
Chronic exposure to a dopamine receptor agonist has been
shown to be associated with the induction of uterine tumors in rats
via indirect perturbation of the estrogen pathway (Alison et al.,
1994). When dopamine agonists such as bromocriptine are
administered to rats, the secretion of prolactin from the pituitary
gland is decreased, which in turn stimulates an increase in estrogen
synthesis resulting in permanent estrus. In humans the luteal phase
is regulated by luteinizing hormone, whereas in rats it is regulated
by prolactin (Harleman et al., 2012). Prolactin is essential for
corpora lutea function and progesterone production and is secreted
during the estrous cycle in rats. Since prolactin is a luteotrophic
hormone in rodents but not humans, this dopamine agonist MoA is
rodent speciﬁc (Allison et al., 1994; Harleman et al., 2012).
For this speciﬁc MoA, the MIE would involve the binding to and
activation of the dopamine receptor. As such, the chemical would
Table 3
Comparison of activity in ER agonist assays captured from the EDSP21 Dashboard; TBBPA vs. known ER agonists (Genistein and Tamoxifen).
Biological process Species (tissue) Assay name AC50(mM)
TBBPA Genistein Tamoxifen
Receptor binding Bovine (uterus) NVS_NR_bER Inactive 0.1061 0.0867
Receptor binding Human (NA) NVS_NR_hER 5.4523 0.0145 0.0518
Receptor binding Mouse (NA) NVS_NR_mERa 4.8519 0.0948 0.1005
Protein complementation Human (kidney) OT_ER_ERaERa_0480 Inactive 3.0788 0.4745
Protein complementation Human (kidney) OT_ER_ERaERa_1440 Inactive 2.6000 0.9033
Protein complementation Human (kidney) OT_ER_ERaERb_0480 Inactive 0.7914 0.3395
Protein complementation Human (kidney) OT_ER_ERaERb_1440 Inactive 1.3521 0.3354
Protein complementation Human (kidney) OT_ER_ERbERb_0480 Inactive 0.1317 0.4977
Protein complementation Human (kidney) OT_ER_ERbERb_1440 Inactive 0.1130 0.1136
Gene expression Human (cervix) OT_ERa_EREGFP_0120 Inactive 1.2010 0.2292
Gene expression Human (cervix) OT_ERa_EREGFP_0480 Inactive 0.9253 0.2018
mRNA induction Human (liver) ATG_ERE_CIS_up Inactive 0.0975 Inactive
mRNA induction Human (liver) ATG_ERa_TRANS_up 33.7989 0.1433 Inactive
Gene expression Human (kidney) Tox21_ERa_BLA_Agonist_ratio Inactive 8.9789 71.8512
Cell proliferation Human (breast) ACEA_T47D_80hr_Positive Inactive 0.0786 0.0348
Gene expression Human (ovary) Tox21_ERa_LUC_BG1_Agonist Inactive 2.7502 Inactive
Table 4
ER agonist bioactivity for TBBPA, genistein, and tamoxifen captured from the EDSP21 Dashboard (http://actor.epa.gov/edsp21/).
Chemical Number of Active assays
(Out of 16)a
Range of Active concentration AC50
mM
ER agonist bioactivity
(AUC)b
TBBPA 3 4.85e33.80 0
Genistein 16 0.015e8.98 0.5380
Tamoxifen 13 0.035e71.85 0.0199
a See Table 5 for speciﬁc assays.
b AUC (agonist) ¼ 1 for 17a-Ethinylestradiol.
Table 5
Bioassay results for TBBPA inhibition of HSD17b4 (hydroxysteroid (17-beta) dehydrogenase 4).
Assaya Target Outcomeb
AID 893 qHTS assay for inhibitors of HSD17 4, hydroxysteriod (17-b) dehydrogenases 4 Chain Ac Active; Reported Potency at 4 mM and 10 mM
AID 893 qHTS assay for inhibitors of HSD17 4, hydroxysteriod (17-b) dehydrogenases 4 Chain Bc Active; Reported Potency at 4 mM and 10 mM
a National Center for Biotechnology Information. Pub Chem Bio Assay Database; AID ¼ 1063379, https://pubchem.ncbi.nlm.nih.gov/bioassay/1063379 (accessed Sept. 19,
2015).
b Overall assay results are designated as active or inactive.
c The structure of Wild-Type Human Hadh2[17b-hydroxysteroid Dehydrogenase Type 10) bound to NAD þ at 1.2 A.
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evaluated to date as a dopamine agonist, although Lai et al. (2015)
did note that in an in vitro study TBBPA resulted in a concentration
dependent inhibition in dopamine uptake of neurotransmitters in
isolated rat brain synaptosomes. In a 28-day repeat dose study
carried out according to OECD407 guidelines, there was no change
in staining of prolactin measured by immunohistochemical stain-
ing in the pituitary gland of control and TBBPA-treated Wistar rats
(0, 100, and 300 mg/kg) (Osimitz et al., 2016; EU, 2006). Addi-
tionally, no histopathological changes were noted in the pituitary in
guideline-based reproductive, developmental, and neurobehavior
studies at doses up to 1000 mg/kg (Cope et al., 2015; EU, 2006).
Although it would be interesting to determine the potential for
TBBPA to be a dopamine agonist, the limited data available suggest
it is most likely not operating through this MoA to cause uterine
tumors in Wistar Han Rats and this MoA is rodent speciﬁc.4.1.3. Disruption in estrogen metabolism
It is important to understand that estrogen homeostasis is
complex and multifactorial. A schematic highlighting selected
portions of the complex metabolism scheme for estrogens is pro-
vided in Fig. 1. As described by Cavalieri and Rogan (2014), estro-
gens are derived from the aromatization of both androstenedioneand testosterone through the activity of aromatase (CYP19) to
estrone and estradiol, respectively. Both estrone and estradiol are
interconverted by hydroxysteroid-dehydrogenase-17b (HSD17b).
Additionally, estrone and estradiol may potentially undergo sulfa-
tion when present in excess. Estrogens are then further metabo-
lized by two main pathways: 1) CYP1A1 catalyzes hydroxylation of
estrone and estradiol preferentially at C-2, and 2) CYP1B1 catalyzes
hydroxylation almost exclusively at C-4. These two catechol es-
trogens (i.e., 2-hydroxy estradiol and 4-hydroxy estradiol) can be
inactivated by conjugation to glucuronides and sulfates, especially
in the liver. In extrahepatic tissues, the most common path of
conjugation of catechol estrogens is O-methylation catalyzed by
catechol-O-methyltransferase (COMT). Oxidation of the catechol
estrogens to quinones is catalyzed by cytochrome P450 or peroxi-
dase and this pathway becomes more competitive when the ac-
tivity of COMT is low.
In the sections that follow, selected key enzymes that could
inﬂuence the bioavailability of estrogens are identiﬁed and dis-
cussed in the context of what is known about effect of TBBPA on the
speciﬁc activity of these enzymes. The enzyme systems identiﬁed
below are also critical in the regulation of tissue speciﬁc estrogen
levels. As such, induction or inhibition of these enzymes by a
chemical, whether competitive or noncompetitive, may result in an
Fig. 1. Schematic of estrogen metabolism (modiﬁcation of that presented by Schicht
et al., 2014). Emphasis is on the metabolism of estradiol with the identiﬁcation of
enzyme systems that would inﬂuence the bioavailability of estradiol (denoted as A, B,
C, and D with dotted circles).
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4.1.3.1. Induction of aromatase (CYP19) (Fig. 1, pathway A).
Aromatase (CYP19) metabolizes testosterone to estradiol. Thus,
overexpression of aromatase could result in excess synthesis of
estrogens in speciﬁc tissues (Miller and O'Neill, 1987; Jefcoate et al.,
2000). Only one in vitro study was identiﬁed in the published
literature with information related to this potential MIE for TBBPA.
Speciﬁcally, Canton et al. (2006) measured the catalytic activity of
CYP19 in human adrenocortical carcinoma cells following exposure
to TBBPA. At a concentration of 7.5 mM, no induction or inhibition
was reported. Although there are currently no speciﬁc data in the
published literature to suggest inhibition or induction of aromatase
in vivo, it is unlikely that aromatase is affected by TBBPA.
4.1.3.2. Inhibition of hydroxysteroid-dehydrogenase-17b (HSD17b)
(Fig. 1, pathway B). When high levels of estradiol are present,
hydroxysteroid-dehydrogenase-17b (HSD17b) converts estradiol to
estrone, which is a less active estrogen than estradiol (Blom et al.,
2001; Karageorgi et al., 2011). As such, inhibition by HSD17b
would potentially increase the bioavailability of estradiol in the
uterus. Blom et al. (2001) demonstrated that in both human and rat
uterine tissue the regulation of local estradiol levels is through
HSD17b activity. In rats, there are two HSD17b isoforms that have
been described, with HSD17b type 2 the predominant isoform in
the uterus. TBBPA has been shown to inhibit HSD17b (Wild-Type
Human Hadh2[17b-hydroxysteroid Dehydrogenase Type 10])
in vitro in high throughput screens reported in the NIH Molecular
Libraries Screening Center Network, 2014 (Table 5). Additionally,
Sanders et al. (2014) reported that following oral administration of
TBBPA at 250mg/kg for 5 days, the gene expression of HSD17b-type
2 was down regulated in both the liver and distal uterus of the rat;
however, HSD17b activity was not measured in this study. If a
decrease in gene expression correlates to a decrease in protein and
then enzyme activity, these data would suggest that there is the
potential for TBBPA to decrease conversion of estradiol to estrone
and could contribute to an increase in estradiol levels and tissue
bioavailability.
4.1.3.3. Induction of CYP1A1 and or CYP1B1 (Fig. 1, pathway C).
As mentioned above, estradiol and estrone can be sulfated bysulfotransferases or oxidized to catechol estrogens by CYP1A1 and
CYP1B1. These catechol estrogens are then further oxidized to
semiquinones and quinones. This pathway is associated with the
generation of reactive oxygen species that can bind to nucleic acids
and damage DNA (Liehr, 2000). An induction of these enzymes
could result in a higher level of catechol estrogens, which are
considered important intermediates in estrogen-related carcino-
genesis. These compounds would be further metabolized to reac-
tive quinones, resulting in the generation of reactive oxygen species
that could in turn lead to tissue damage and potentially increase
mutation frequency. With increased estradiol bioavailability due to
a decrease in its conjugation (as described above in pathway A),
there is the opportunity for these estrogens to be shuttled through
these oxidative metabolic pathways.
To date the only evidence to suggest that these enzymes may be
induced by TBPPA is information presented at a scientiﬁc confer-
ence. In this study by Sanders et al. (2014), TBBPA (250 mg/kg) was
administered orally for 5 days to femaleWistar Han rats resulting in
an increased expression of CYP1B1 in uterine tissue and CYP2B1 in
liver tissue. If this increase is sustained there is the potential that a
higher level of estradiol catechols would be formed ultimately
being further metabolized to reactive quinones that bind to DNA
and contribute to the development of uterine adenocarcinomas.
These authors also reported a down-regulation of Comt expression
in the liver with administration of TBBPAwhich could contribute to
decreased inactivation of catechol estrogens. Other than the report
by Sanders et al. (2014), there are no other experimental data to
suggest the induction of CYP1B1 by TBBPA. Germer et al. (2006)
showed that oral doses of TBBPA of up to 300 mg/kg for 4 weeks
in rats did not induce CYP1A2, CYP2B1 or CYP3A mRNA expression,
protein expression, or protein activities of these enzymes. In
studies reported by Behnisch et al. (2003) and Hamers et al. (2006),
TBBPA did not induce aryl hydrocarbon receptor (AhR) responsive
genes, or AhR-dependent 7-ethoxyresoruﬁn-O-deethylase activity,
suggesting overall that these CYP enzymes are not induced.
Although the induction of CYP1A1 and or CYP1B1 is most likely not
the MIE for TBBPA, increased bioavailability of estrogens due to
inhibition of estrogen sulfotransferases and or HSD17b would
provide a higher level of estradiol at the tissue level available to be
metabolized through this pathway.
4.1.3.4. Inhibition of estrogen sulfotransferase (Fig. 1, pathway D) and
or glucuronyltransferase.. Estrogen primarily occurs in three forms
in females: estrone (E1), estradiol (E2), and estriol (E3) (Rizner,
2013). The metabolism of these estrogens can play a large role in
the development of diseases, including endometrial cancer. Estro-
gens can undergo phase I and phase II metabolism involving
oxidation by cytochrome P450s, O-methylation by catechol-O-
methyltransferase, conjugation with glutathione, sulfation by sul-
fotransferases (SULT enzymes), and glucuronidation by UDP-
glucuronosyltransferase (UGT), among other changes as illus-
trated in Fig. 1. Once estrogens undergo sulfate or glucuronic acid
conjugation, they have decreased activity (i.e. decreased ability to
bind to ERs) as well as increased elimination (Xu et al., 2012).
Wang and James, 2006 provide information on the tissue dis-
tribution of sulfatransferases (SULTs) in humans with identiﬁcation
of the major substrates including phenols, catecholamines, thyroid
hormone, estrogens and hydroxysteroids. The endometrium is an
estrogen responsive tissue that expresses sulfotransferases
involved in estrogen metabolism (Utsunomiya et al., 2004). The
isoform, SULT1E1, has been shown to exhibit a particularly high
afﬁnity for estradiol and is primarily responsible for estrogen
metabolism in humans (Falany et al., 1998; Coughtrie et al., 2002;
Xu et al., 2012). In fact, a correlation between SULT1E1 and estro-
gen carcinogenesis has been identiﬁed in estrogen-dependent
D.S. Wikoff et al. / Regulatory Toxicology and Pharmacology 77 (2016) 143e159150cancers (Choi et al., 2005; Hirata et al., 2008). With respect to es-
trogen metabolism, one study found that estradiol glucuronidation
was more active in the uterus of Wistar rats than estradiol sulfation
through SULT enzymes as a group (Blom et al., 2001). However it is
important to note these animals were ovariectomized, and activity
of SULT1E1 was not speciﬁcally evaluated; further, the concentra-
tion of the substrate would most likely determine whether it is
glucuronidated or sulfated.
Similar to estrogen, TBBPA is metabolized to both sulfate and
glucuronide conjugates. Because of these overlapping metabolic
processes, TBBPA has the potential of competing with the same
enzyme systems involved in the conjugation of estrogens. To date,
there are no in vivo studies in rats that evaluate the TBBPA inhibi-
tion of either estrogen sulfotransferases or glucuronyltransferases.
However, several lines of evidence support the ability of TBBPA to
bind to and inhibit estrogen sulfotransferases in several in vitro
assays and through computational predictive studies (references
cited in Table 6). Two in vitro studies were conducted using re-
combinant human SULT1E1/SULT1A1 expressed in S. typhimurium,
V79-1E1 Chinese hamster cell line along with one study using
human cytosol as a source of enzyme reported by Kester et al.
(2002) and Hamers et al. (2006). Kester et al. (2002) reported
that TBBPA inhibits estradiol sulfotransferase with IC50 values
ranging from 12 to 33 nM. In another study, TBBPAwas found to be
a potent inhibitor of estradiol sulfotransferase (IC50 ¼ 16 nM) and
was found to be approximately 13 times more potent than penta-
chlorophenol (PCP), a known inhibitor of sulfotransferase (Hamers
et al., 2006). Although the speciﬁc type of TBBPA inhibitionwas not
evaluated by LineweavereBurk analysis, other structurally similar
chemicals were identiﬁed as non-competitive inhibtors (Hamers
et al., 2006; Kester et al., 2002). In another study Gosavi et al.
(2013) evaluated the crystal structure of estrogen sulfotransferase
and found through computation modeling that TBBPA binds to the
same site as estradiol. This is consistent with ﬁndings in a QSAR
study which evaluated binding to this enzyme and found that
TBBPA fulﬁlled the chemical structure criteria that would predict
potent inhibition of estrogen sulfotransferase (Harju et al., 2007).
Taken together, these studies provide evidence to support TBBPA
inhibition of estrogen sulfotransferase (SULT1E1 or SULT1A1)
(Fig. 1).
Until recently, data characterizing potential inhibition of estro-
gen sulfotransferases were limited to in vitro assays and compu-
tational models. However, data from a recent study provide
evidence of an inhibition in vivo, as well as assessment of dose on
the impact of such (Borghoff et al., 2016). In this study by Borghoff
et al. (2016), the effect of dose and repeated administration of
TBBPA on the level of TBBPA, TBBPA-glucuronide (GA) and TBBPA-Table 6
Lines of evidence from the published literature characterizing TBBPA-induced inhibition
Reference Assay(s) Endpoints
Kester
et al.
(2002)
In vitro; Recombinant human SULT1E1 expressed in
Salmonella typhimurium, human liver cytosol,
cofactor PAPS, 3H-estradiol and TBBPA
Inhibition of SULT1E1;
LineweavereBurk analy
Hamers
et al.,
2006
In vitro; Recombinant human SULT1E1 expressed in
a V79-1E1 Chinese hamster cell line; cofactor PAPS,
3H-estradiol and TBBPA
Inhibition of SULT1E1;
LineweavereBurk analy
Harju
et al.,
2007
QSAR model for E2-SULT inhibition A QSAR model for E2-SU
criteria for potent inhib
that there was two vicin
group with planar hydr
Gosavi
et al.,
2013
X-ray crystallography to obtain atomic detail of
binding models of TBBPA and estradiol to estrogen
sulfotransferase
Atomic detail of bindin
estradiol to SULT1E1
a Overall assay result is designated as positive or negative.
b Other potent inhibitors of SULT1E1 with IC50 values ranging from 0.18 to 34 nM hasulfate (S) conjugates in plasma, liver and uterus of female Wistar
Han rats administered TBBPA (50, 100, 250, 500 or 1000 mg/kg) for
28 consecutive days was assessed, using TBBPA sulfation as a sur-
rogate for evaluating the estradiol sulfation since they are conju-
gated by the same estrogen sulfotransferases. At 4e8 h following
administration of 50 mg/kg TBBPA (a dose that is 10  lower than a
dose associated with uterine tumors), the mean concentration of
free TBBPA in plasma was approximately 1478 nM, an estimated
45e123  higher than the value associated with the inhibition of
estrogen sulfotransferase by TBBPA reported in vitro (12e33 nM)
(Kester et al. (2002). The ﬁndings from this in vivo study in rats
(Borghoff et al., 2016) demonstrate that the concentration of TBBPA
in the plasma is well above the concentration shown to inhibit
sulfotransferase activity in vitro. Data from this study also demon-
strate that administration of the same high doses of TBBPA asso-
ciated with the induction of uterine tumors also result in a
disruption in the balance of conjugates reﬂected by a decrease in
the TBBPA-S/TBBPA-GA ratio; this dose-dependent decrease in the
ratio supports saturation of the sulfation pathway at dose levels of
250 mg/kg and above.
The in vitro data on TBBPA's ability to inhibit estrogen sulfo-
transferase coupled with the knowledge that administration of the
same high doses of TBBPA that were associated with the induction
of uterine tumors also result in a disruption in the balance of
conjugates as demonstrated by the decrease in the TBBPA-S/TBBPA-
GA ratio in vivo, provided multiple lines of evidence to support that
the MIE for TBBPA induction of uterine tumors in rats is through its
ability to inhibit sulfotransferase activity.
4.2. Key events anchoring the MIE to the AO
The key events anchoring the proposed MIE (i.e., inhibition of
estrogen sulfotransferase) to the AO were evaluated in the context
of an AOP as outlined in Fig. 2. Data available to characterize the
potential key events inWistar Han rats are described in detail in the
sections that follow. Consistent with an AOP framework approach,
these events are not considered to be chemical speciﬁc; however,
for each key event, the biological aspects of the event are described
along with evidence unique to TBBPA.
4.2.1. KE: increased estrogen bioavailability
Potent inhibitors of estrogen sulfotransferases have the poten-
tial to increase the bioavailability of estradiol in target tissues,
thereby causing an estrogenic effect (e.g., changes in metabolism of
estrogens resulting in higher estradiol levels that interact with ER
receptors, rather than the compound directly binding to and acti-
vating the ER) (Wang and James, 2006). Although no directof Sulfotransferase.
Resulta
type of inhibition was not evaluated by
sis
Positive;
IC50 ¼ 12e33 nMb
type of inhibition was not evaluated by
sis
Positive;
IC50 ¼ 16nMb
LT inhibiting potency demonstrated that
ition of estrogen sulfotransferase was
al chlorine substitutes around a hydroxyl
oxylated hydrocarbons
TBBPA fulﬁlled these chemical structure
criterion to predict potent inhibition of
estrogen sulfotransferase
g based on crystal structures; TBBPA and Positive; binding afﬁnities of TBBPA and
estradiol to SULT1E1 estimated to be
similar
ve been identiﬁed in mammalian species (Kester et al., 2002).
D.S. Wikoff et al. / Regulatory Toxicology and Pharmacology 77 (2016) 143e159 151evidence linking inhibition of estrogen sulfotransferase and an in-
crease in the bioavailability of estrogens in the Wistar Han rat was
identiﬁed, there are data demonstrating that increase in estrogens
would be responsible for an increase in estrogenic activity, and that
an increase in estrogens is correlated with uterine tumors in rats.
For example, Elsinghorst et al. (1984) proposed that high levels
of hormones during a constant estrous state and/or chronic infec-
tion play an important role in uterine tumor development. Addi-
tionally, numerous investigators have shown that an estrogen
imbalance in rats is associated with endometrial carcinomas
(Hilliard and Norris, 1979; Lingeman, 1979; Fox, 1984). Further,
Nagaoka et al. (1990), have shown that an increased estradiol
(E):progesterone (P) ratio plays a critical role in the occurrence of
spontaneous endometrial adenocarcinomas in the Donryu rat, a rat
model with a 35.1% incidence of these tumors. An increased E:P
ratio has also been shown to play a role in the development of
uterine tumors in F344 rats (Tang et al., 1984). In this strain,
changing the ratio, either induced or via a naturally constant estrus
status at 12 months of age, led to focal glandular hyperplasia that
did not progress to more advanced adenomatous hyperplasia until
29 months of age. The ﬁndings led the authors to suggest that the
development of a progesterone-insensitive state associated with
the aged endometrium may be required for the progression to
advanced adenomatous hyperplasia and uterine endometrial
adenocarcinoma in rats.
Data involving a direct evaluation of a potential increase in
circulating or tissue-speciﬁc levels of estradiol following exposure
to TBBPA are not available. In the absence of this information, other
data are limited to indirect evidence supporting an increase in
bioavailability of estrogen following TBBPA administrations. First,
there are indications that estrogen stimulated genes are induced in
the uterus following four days of TBBPA administration (Sanders
et al., 2014). Second, in a 90-day study of high dose exposures to
TBBPA (EU, 2006), treatment-related decreases in serum glutamic
pyruvic transaminase was observed in females at the high dose
(1000 mg/kd-day). As serum glutamate is inversely associated with
estrogen levels (Tsesis et al., 2013; Zlotnik et al., 2011), this supports
the hypothesis that TBBPA exposure results in an increase in
circulating levels of estrogen.Binding and 
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Fig. 2. Proposed MoA for TBBPA-induced uterine tumors in the context of an AO4.2.2. KEs: increased estrogen- related gene expression and cell
proliferation
Although the MIE of TBBPA-induced uterine tumors most likely
does not involve direct binding to the ER receptor, a disruption of
estrogen metabolism leading to increase estrogen bioavailability
would essentially lead to increase in ER activation. Estrogen and its
related signaling molecules are important to consider in the eval-
uation of TBBPA toxicity, as estrogen signaling plays a critical role in
uterine cell health and regulation (Rizner, 2013). Evaluating these
interactions at the gene expression level help elucidate potential
links between TBBPA exposure, estrogen signaling, and disease.
Changes in estrogen-responsive gene expression, linked with
changes in estrogen signaling at the protein level, ultimately in-
ﬂuences cell cycle and cell proliferation (Rizner, 2013). At the
phenotypic level, increases in estrogen and its related signaling can
cause uterine tissues to rapidly grow in size, as demonstrated by
the common use of the rat uterus as a target organ for the in vivo
screening of estrogen agonists and antagonists.
To date, gene expression changes in the uterus associated with
TBBPA exposure have only been evaluated by one study (Sanders
et al., 2014). This study evaluated the expression levels of a sub-
set of genes in the distal and proximal uterus of female Wistar Han
rats treated with 250 mg/kg/day TBBPA for ﬁve consecutive days.
Twenty-four hours following treatment, signiﬁcantly increased
expression of estrogen receptor 1 (Esr1) and estrogen receptor 2
(Esr2) was identiﬁed in the distal uterus, and increased expression
of Esr1 was identiﬁed in the proximal uterus. Other key genes
involved in the estrogen signaling pathway, identiﬁed in the cur-
rent analysis using the KEGG Estrogen Signaling Pathway (KEGG,
2015), were also characterized as having increased expression
levels following TBBPA exposure (Sanders et al., 2014). These genes
include Cyp1b1 (cytochrome P450, family 1, subfamily b, poly-
peptide 1), Igf1 (insulin-like growth factor 1), Thra (thyroid hor-
mone receptor alpha), Thrb (thyroid hormone receptor beta), and
Ttr (transthyretin). It is important to note that not all gene
expression changes related to estrogen signaling were increased.
For example TBBPA resulted in decreased expression of Esr2 in the
proximal uterus. However, there are some lines of evidence
showing that, in some instances, ESR2 may act as a repressor of
ESR1, in which lower expression of ESR2 may lead to enhanced
estradiol action via increased ESR1 levels in endometrial cancerllular Organ
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related to estrogen signaling was observed in the uterus of TBBPA
exposed rats.
No other studies have assessed TBBPA-associated gene expres-
sion changes in the uterus, to our knowledge, representing an
important data gap. In order to further evaluate whether TBBPA-
associated changes in gene expression are potentially related to
estrogen, the Comparative Toxicogenomics Database was queried
for genes modiﬁed by TBBPA exposure in vitro and/or in vivo in
additional tissues besides the uterus (CTD, 2015). These genes were
then compared to genes involved in the KEGG Estrogen Signaling
Pathway (pathways IDs hsa04915, rno04915, and mmu04915 for
human, rat, and mouse, respectively). The following genes were
identiﬁed as both increased in expression by TBBPA exposure in
animal models and involved in estrogen signaling: Hbegf (heparin-
binding EGF-like growth factor), Hspa1l (heat shock protein 1-like),
Mmp2 (matrix metallopeptidase 2), Mmp9 (matrix metal-
lopeptidase 9), and Pik3r5 (phosphoinositide-3-kinase, regulatory
subunit 5). These ﬁndings further support the proposed key event
of TBBPA inducing increased expression of genes involved in es-
trogen signaling, potentially leading to increased cell proliferation/
hyperplasia in rats.
In addition to gene expression increases related to estrogen
signaling, TBBPA has also been shown to cause increased cell pro-
liferation in rats following chronic exposure (NTP, 2014). In the 2-
year rat cancer bioassay, endometrial adenocarcinomas in rats
treated with high doses of TBBPA exhibited ﬁbroblast proliferation
and thick stroma in many cases (NTP, 2014).
4.2.3. KEs: generation of reactive quinones and subsequent DNA
damage
As described by Cavalieri and Rogan (2014), estrogens are nor-
mally metabolized through the catechol estrogen pathway that
involves enzymes that are critical to estrogen homeostasis (Fig. 1).
Maintaining estrogen homeostasis through its metabolism will
determine the level of “active” estrogens in a tissue, as well as the
level of estrogen that is metabolized via oxidation of catechol es-
trogens, which as already discussed are then metabolized to qui-
nones that are reactive with DNA and associated with estrogen-
initiated cancers (Yager and Liehr, 1996). The metabolism of es-
trogens is based on a balance of both activating and protective
enzymes to minimize its oxidation to catechol estrogens and sub-
sequently DNA reactive quinones. Disruption of homeostasis in
estrogen metabolism could potentially lead to excessive formation
of catechol quinones. Although a variety of endogenous and exog-
enous factors can disrupt estrogen homeostasis including diet,
environment, lifestyle, aging and genetic factors, exposure to spe-
ciﬁc chemicals such as TBBPA may cause either an induction or
inhibition in the enzymes critical in the metabolism of estrogens,
which in turn may lead to an increase in estrogens and an increase
in metabolism of estrogens to reactive quinones.
Evidence to suggest that TBBPA may indirectly be associated
with increased Tp53 mutation frequency in uterine adenocarci-
nomas from the NTP bioassay was described in a recent report by
Harvey et al. (2015). The NTP evaluated the mutation frequency of
Tp53 by non-randomly selecting tumors from 16 TBBPA dosed
Wistar Han rats and compared the frequency (combined across
dose groups) to spontaneously induced tumors from control ani-
mals from other 2-year studies conducted in Wistar Han rats
(which involved animals from both corn oil gavage studies, as well
as inhalation studies; Table S1). In an independent assessment of
these data, it was discovered that the data for these analyses were
differentially reported among the various NTP publications
(Table S2), thus limiting the reliability and utility of these data in
our assessment. It is notable, however, that when ﬁndings based onindividual dose groups were considered, just as NTP evaluates tu-
mors from the individual dose groups separately, the 250 and
1000 mg/kg treatment groups showed signiﬁcant (p < 0.05) effects
while the 500 mg/kg treatment group did not.
Mutation of Tp53 is an important effect to consider when eval-
uating chemically-induced tumors, as TP53 plays a critical role in
apoptosis regulation and, when mutated, can contribute to the
development of various cancers (reviewed in Rager, 2015). Further,
Tp53 mutations have also been identiﬁed in human endometrial
cancer and are associated with a late event in the development of
aggressive high-grade endometrial tumors (Lax et al., 2000).
However, when the available Tp53 data are considered as a whole
for TBBPA, these data do not provide strong support for the idea
that tumors in animals administrated TBBPA might have a higher
frequency of Tp53 mutations. Despite the shortcomings that pre-
clude the use of the available Tp53 mutations data quantitatively,
they may suggest that mutations in Tp53may play a secondary role
in the development of tumors following administration of high
dose levels of TBBPA, and thus are included in the proposed AOP
(Fig. 2). However, additional data are clearly needed to better
characterize this potential event.
4.2.4. KEs: hyperplasia
A critical change that frequently occurs prior to the develop-
ment of uterine tumors is hyperplasia. Endometrial hyperplasia is
generally characterized as a thickening or enlargement of the
uterine tissue that occurs as a result of increased cell proliferation.
There are two major types of endometrial hyperplasia: cystic and
glandular hyperplasia (Yoshida et al., 2012; Klaunig et al., 2015).
Cystic endometrial hyperplasia is not recognized as preneoplastic,
whereas glandular endometrial hyperplasia is recognized as a po-
tential precursor to adenocarcinoma. In particular, atypical glan-
dular hyperplasia of the uterine epithelium is commonly observed
in rats prior to endometrial tumor formation (Yoshida et al., 2012;
Klaunig et al., 2015). Both forms, preneoplastic and non-neoplastic
hyperplasia, were observed in the TBBPA rat bioassay (Table 1)
(NTP, 2014). Atypical endometrial hyperplasia, the form that is most
closely linked to tumorigeneisis, was statistically associated with
TBBPA treatment during the residual longitudinal inspection of the
uterus. These proliferative lesions were characterized as affecting
either the glandular epithelium and/or uterine surface epithelium.
Notably, these lesions were not identiﬁed upon original transverse
inspection of the uterine tissues. In contrast, the incidence of cystic
endometrial hyperplasia was identiﬁed as increased in all dosed
groups, and was statistically signiﬁcant in animals in the 1000 mg/
kg dose group, in the original transverse review of the uterine
samples. However, the residual longitudinal review and the com-
bined reviews did not support this increase. Rather, the ﬁndings of
the longitudinal review suggested that the incidences of cystic
endometrial hyperplasia were not treatment-related (NTP, 2014).
4.2.5. AO: uterine tumors
Uterine tumors that can occur in rats, in general, include
epithelial neoplasms such as adenomas, adenocarcinomas, squa-
mous cell papillomas and non-epithelial tumors such as ﬁbrosar-
comas, endometrial stromal polyps, leiomyomas, and
hemangiosarcomas (reviewed in Klaunig et al., 2015). Several of
these neoplasms are common; however, adenocarcinomas in
particular typically occur at a low incidence in the most commonly
used strains of rats. As described previously, adenomas, adenocar-
cinomas, and Mixed Müllerian tumors (MMMTs) were observed in
Wistar Han rats following chronic exposure to high doses of TBBPA,
and the statistical signiﬁcance of such was greatest when all tumor
types and all methods utilized to evaluate the tissues (i.e., trans-
verse and longitudinal, were combined (Table 1).
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combined tumors, however, warrants some caution given an
apparent high spontaneous incidence, the lack of historical control
data from NTP for this strain, and the lack of comparison data for
the approach utilized to assess the tissues. This NTP study (2014)
was the ﬁrst study where they used longitudinal sectioning to
evaluate the uterus, and, while this new approach provided useful
information, there is also uncertainty as there are no historical data
available for the incidence of these lesions using the longitudinal
approach. This lack of historical data for the longitudinal approach
is compounded by the lack of robust historical control data on the
incidence of uterine tumors in the Wistar Han rat as the NTP only
used this strain of rats for a very short period of time. In an inde-
pendent assessment of available data (Table S1), it appears that the
Wistar Han rats used in the NTP bioassays have a high background
incidence of uterine adenocarcinomas (2e18%) relative to that
observed in F344 (0.29%) (NTP, 2013; Klaunig et al., 2015). Other
studies in the literature also indicate that Wistar Han may have a
high background rate of uterine tumors (Deerberg et al., 1981;
Harleman et al., 2012; Poteracki and Walsh, 1998), with in-
cidences up to 39% (Deerberg et al., 1981). As an additional point of
interest, an inverse relationship between uterine and mammary
tumors in the Wistar rats has been previously reported (Harleman
et al., 2012). In the TBBPA bioassay, no treatment-relatedmammary
tumors were observed, which is consistent with the spontaneous
pattern observed. Taken together, these data provide evidence for
potential strain sensitivity to this adverse outcome, and thus should
be consideredwhen evaluating the overall strength of the evidence.
5. Plausibility and human relevance
To understand the risk of humans developing uterine tumors at
TBBPA exposure concentrations that are relevant to humans, the
plausibility of the MoA occurring in humans needs to be evaluated
in the context of the MIE and KEs identiﬁed above. As such, data
were reviewed to characterize concordance of the events in the
AOP relative to the body of toxicological evidence available for
TBBPA, concordance of the events in the AOP between rodents and
humans, as well as the plausibility and relevance of the MIE and
other key events in humans when kinetic and dynamic factors are
considered (Meek et al., 2003). The ﬁndings, discussed in more
detail in the sections that follow, support that the AOP could
operate in both humans and rats, though important differences
exist when kinetic and dynamic inﬂuences on the MIE are
considered. Notably, data show that the MIE is dose- and time-
dependent, and speciﬁcally only occurs at high doses following
repeated exposures. Thus, when current levels of human exposure
are considered, the MIE and subsequent key events for the devel-
opment of TBBPA-induced uterine tumors are thus highly unlikely
occur in humans.
5.1. Assessment of concordance with other toxicity data
In considering the plausibility and relevance, assessments of the
concordance of the overall MoA for TBBPA, as well as concordance
of the MIE speciﬁcally, are curious when compared to ﬁndings from
other toxicity studies that evaluate endpoints associated with
endocrine activities. In all three 90-day toxicity studies that have
been conducted in F344, Wistar Han, and CD rats at oral gavage
doses of up to 1000 mg/kg (NTP, 2014; Osimitz et al., 2016), there
were no signiﬁcant adverse effects noted (e.g., clinical signs, body
and organ weights, histopathology, urinalysis, neurological anal-
ysis, serum chemistries, etc). As already discussed, the general MIE
for uterine tumors is hypothesized to be associated with a disrup-
tion in the metabolism of estrogens either through the induction orinhibition of its key systems. If TBBPA caused signiﬁcant enzyme
induction, it would be anticipated that there would be an increase
in liver weights observed in the subchronic toxicity studies, how-
ever this was not consistently the case. Additionally, when
considering these ﬁndings relative to the proposed MIE (i.e., inhi-
bition of estrogen sulfotransferase), it is not clear at this time what
early indications might have been expected in the 90-day studies
(e.g., does not allow for impact of aging). It is anticipated that if
estrogen levels were high at the 90 day time point, there would
have been indication of uterine hyperplasia or perhaps changes in
estrus cycle in the female rats. The statistically signiﬁcant changes
observed in serum thyroxine (T4) levels in these 90-day studies
may be associated with the proposed MIE involving inhibition of
sulfotransferase, as these enzymes are also involved with hormone
metabolism.
Other studies in the literature have assessed responses associ-
ated with estrogenic activity following administration of TBBPA. In
an OECD-guideline compliant study, TBBPA was administered by
either subcutaneous injection or oral gavage daily for seven days (at
doses of up to 1000 mg/kg-day; the maximum limit in the assay)
and was found not to be an estrogen agonist or antagonist in
ovariectomized mice (Ohta et al., 2012). This ﬁnding is consistent
with the proposed MoA, as direct binding and receptor agonism
was clearly shown not to be a plausible MIE (as discussed above). In
a separate uterotrophic assay, though not an OECD-guideline based
study, Kitamura et al. (2005) reported an increased, however not
dose dependent, uterus to body weight ratio in ovariectomized
mice administered TBBPA via intraperioneal injection (20, 100, 300
or 500 mg/kg-day), for 3 days. These authors concluded that TBBPA
had estrogenic activity in this model. However, unlike the OECD-
guideline study in which wet and blotted uterine weights were
evaluated to assess an uterotrophic response, the Kitamura et al.
(2005) study measured relative uterine weights only. The
different responses between these two uterotrophic studies appear
to be more related to the endpoints analyzed than to doses and or
routes of administration.
When evaluating the concordance of endocrine-mediated ef-
fects across studies, the duration of exposure is an important
consideration. For example, it is possible that subchronic exposure
to TBBPA, even at high doses, does not result in sustained estrus or
changes in cyclicity, both of which are clear indicators of increase
estrogen bioavailability. Though perhaps when high-dose exposure
is prolonged, responses are evident in aging animalse a relation-
ship demonstrated to be inﬂuential in the MoA (and relevance) of
decamethlcyclopentasioloxane-induced rat uterine endometrial
adenocarcinomas (Klaunig et al., 2015).
5.2. Assessment of concordance of animal and human responses
Uterine endometrial tumors are the fourth most common ma-
lignancy in U.S. women, with an estimated 50,000 new cases per
year (Siegel et al., 2013). Endometrial cancers in women have been
broadly classiﬁed into two groups; type I endometrioid tumors
linked to estrogen excess, obesity, hormone-receptor positivity, and
favorable prognosis compared with type II, primarily serous, tu-
mors that aremore common in older, non-obesewomen and have a
worse outcome. As described by Plataniotis et al. (2010), adeno-
carcinomas are divided into two categories: 1) Type I, which are
usually estrogen-related and arise from a precursor lesion (i.e.,
atypical hyperplasia), and 2) Type II endometrial cancers that are
not hormone-dependent and are usually grade III adenocarci-
nomas, papillary serous and clear cell carcinomas and MMMTs.
These Type II tumors have p53 mutations, as well as loss of het-
erozygosity at a number of chromosomal loci.
With respect to the proposed AOP, several lines of evidence are
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human responses. Beginning with the MIE, multiple in vitro assays
and computational models have demonstrated that TBBPA binds to
and inhibits human estrogen sulfotransferase (Table 6). Also, ki-
netic investigations in humans demonstrate that TBBPA is metab-
olized to both sulfate and glucuronic acid conjugates (Schauer et al.,
2006). Additionally, data from a comparative in vitro metabolism
study using rat and human microsomes demonstrated that there
were nomajor qualitative differences of TBBPAmetabolism into the
corresponding glucuronide and other metabolites between species
(rats and humans) in the range of concentrations (20e200 mM)
tested (Zalko et al., 2006). Together, these data support that theMIE
could be initiated in both animals and humans under high TBBPA
dose levels identiﬁed.
With respect to sulfotransferse inhibition by TBBPA and subse-
quent increased estrogen bioavailability, evidence in animals is
limited to data recently published by Borghoff et al. (2016). These
data demonstrated a limitation in the sulfation of TBBPA at high
dose levels. There are no data available at this time to directly
characterize the relationship between sulfotransferse inhibition
and increased estrogen bioavailability for TBBPA in humans. How-
ever, there is data available from an in vitro study in which hy-
droxylated PCBs were shown to be strong inhibitors of human
estrogen sulfotransferases in which the authors suggested that
although inhibition of sulfotransferases might not be associated
with signiﬁcant changes in circulating estradiol levels, bioavail-
ability in estrogen-sensitive tissues such as the endometrium,
could be greatly impacted by this change (Kester et al., 2002).
It is well documented that a disruption in estrogen homeostasis
is a risk factor in development of uterine tumors in both rodents
and humans (IARC, 2012). In humans, endometrial cancer is a dis-
ease that has been linked to prolonged exposure to estrogen when
unopposed by progesterone (Karageorgi et al., 2011) and is most
often associated with increases in exposure to endogenous estro-
gens (Rizner, 2013), which is concordant with responses in rats
(Lingeman, 1979; Hilliard and Norris, 1979; Elsinghorst et al., 1984;
Fox, 1984; Nagaoka et al., 1990).
As discussed previously, there are limited data suggesting that
mutations in Tp53 may play a role in the development of tumors
following high doses of TBBPA in rodents. TP53 mutations in hu-
man endometrial cancer are more abundant in high-grade tumors
with poor prognosis that are often estrogen-independent (Lax et al.,
2000; Bansal et al., 2009 found in Nagy et al., 2014). Tp53mutations
have been identiﬁed in human endometrial cancer and are asso-
ciated with development of aggressive high-grade endometrial
tumors (reviewed in Liu, 2007). Harvey et al. (2015) discussed
concordance between animal and human responses involving Tp53
mutations, stating that changes in gene expression and mutation
spectra found in human endometrial carcinoma were mostly
similar to those identiﬁed in rat uterine carcinomas. These authors
stated that changes in gene expression and mutation spectra found
in human endometrial carcinoma were primarily similar to those
identiﬁed in rat uterine carcinomas, regardless of TBBPA exposure.
Given the limited nature of these data, further investigation is
needed to assess the concordance of Tp53mutations across species.
With respect to hyperplasia, atypical endometrial hyperplasia
has been characterized as a pre-neoplastic lesion (Bartels et al.,
2012; van der Zee et al., 2013), and is considered a signiﬁcant risk
factor for the development or coexistence of endometrial cancer.
Among patients with atypical endometrial hyperplasia, 22e25%
will eventually develop cancer (Kurman et al., 1985). Most cases of
atypical hyperplasia in women are associated with high levels of
estrogens with insufﬁcient levels of progesterone-like hormones.
Consistencies in observations for both hyperplasia and tumors
histopathology in Wistar Han rats relative to human have beendescribed by Dunnick et al. (2015) and Harvey et al. (2015). Harvey
et al. (2015) compared the morphological features of the uterine
tumors in TBBPA administered rats to those observed in humans
and concluded these rat uterine carcinomas resemble those of
high-grade type 1 tumors in women. In reaching this conclusion,
however, the authors also noted that some morphological features
were similar to human high-grade type I endometrial carcinoma,
whereas other features (e.g. Her2 overexpression and increased
Tp53 mutation frequency) were similar to human type II endome-
trial carcinoma. When considered collectively, although the TBBPA-
induced uterine tumors in rats appear to be similar to human ad-
enocarcinomas, classiﬁcation as to the type of endometrial tumor
(Type 1 vs Type 2) is not clear at this time, most likely due to the
lack of sufﬁcient information to allow for meaningful comparisons
of molecular genetic features. Characterization of the molecular
etiology of the rat tumors relative to what is known about human
tumors is necessary to support the hypothesis that the tumor
development is estrogen driven.
5.3. Role of kinetic and dynamic factors in determining human
relevance
Consideration of kinetic and dynamic factors is a critical aspect
of characterizing potential human health risks (Meek et al., 2003,
2014) associated with exposure to TBBPA. Evidence presented
supports that the MoA underlying the induction of uterine tumors
involves disruption of the metabolism of estradiol via competition
for the same enzymes that inactivate and eliminate estradiol. As
such, the relevance of the responses achieved in rats relative to
humans under conditions of exposure is highly dependent on a
characterization of the enzymes involved in the metabolism of
estrogens, as well as the tissue speciﬁc concentrations of TBBPA
that would cause an inhibition or induction of these key enzymes
thereby resulting in a biologically meaningful increase in estrogen
bioavailability.
Schauer et al. (2006) demonstrated that the metabolic pathways
for TBBPA appear to be similar in humans and rats. However, the
human data are limited to kinetic characterizations following
exposure to a low dose of TBBPA (though not particularly low
relative to typical human environmental exposures) relative to
dose levels used in rodent studies. The studies conducted in rodents
are generally limited to kinetic characterizations following
administration to high dose levels. This is important given that in
Wistar Han rats (the stain used in the NTP bioassay), TBBPA elim-
ination pathways appear to become saturated at high doses of
TBBPA (Knudsen et al., 2014). Data are not available to determine if
alteredmetabolic proﬁles of TBBPA or estrogens would be observed
in humans following the high dose levels of TBBPA proposed to be
associated with an estrogen imbalance in rats. However, compari-
sons of internal dosimetry can be made based on available data
(Table 7). Borghoff et al. (2016) showed a dose-dependent decrease
in the ratio of TBBPA-S to TBBPA-GA in liver, plasma, and uterus
suggesting that the sulfation pathway becomes limited at high
doses (levels of ~250 mg/kg and above). These data are consistent
with Knudsen et al. (2014), who reported saturation of elimination
pathways at high doses and provided evidence that the balance of
conjugates can change with dose level of TBBPA. When the animal
and human datasets are compared (Table 7), there are orders of
magnitude differences between TBBPA plasma concentrations in
rats associatedwith a limitation in the sulfation of TBBPA relative to
serum concentrations of TBBPA measured in humans. Such com-
parisons are even more stark when one considers that the majority
of samples evaluated in human studies reported in the literature
have levels below the limit of detections (e.g., Cariou et al., 2008
reported detectable measures in only 30% of samples, and
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the 75th percentile). These internal dosimetry comparisons result
in a ﬁnding similar to that achieved with external dosimetry
comparisons (Wikoff et al., 2015).
It is notable that there is uncertainty in making such compari-
sons given the signiﬁcant variations in the level of reporting, as-
sumptions required to standardizing concentrations, and lack of
information in selected studies to determine if the levels of TBBPA
reported represent free TBBPA or total TBBPA (freeþ conjugated). It
is also important to note that TBBPA, as well as estrogens, can be
glucuronidated and/or sulfated (Fig. 1). As such, if sulfation is
inhibited, one might expect an increase in glucuronidation of
TBBPA along with estrogens with increased dose level of TBBPA. To
this point, there are a number of parameters that can contribute to
the balance in conjugation pathways including: species, strain and
tissue speciﬁcity of the isoforms of both glucuronyltransferases and
sulfotransferases, as well as deconjugation enzymes such as b-
glucuronidase and sulfatase that ultimately play a role in the bal-
ance of these conjugates available in vivo. Such complexities must
be carefully considered when comparing datasets, and thus limit
the ability to make meaningful comparisons to in vitro binding and
inhibition assays.
In summary, kinetic factors of the MIE are ultimately the drivers
for the development of TBBPA-induced uterine tumors. The likely
inhibition of key metabolic enzymes at high doses has a clear
impact on the MIE: ﬁrst, in determining at what dose the TBBPA
kinetics become altered in rodents, and second, how these changes
inﬂuence a prolonged (chronic) change in conjugation of estradiol
due to inhibition of sulfotransferase by TBBPA. Based on available
data, the TBBPA concentrations measured in the human population
would not be sufﬁcient to impact the sulfation of estrogen in vivo,
and hence would not contribute to an increase in estrogen
bioavailability needed to stimulate subsequent KEs that could lead
to uterine tumor development. Such conclusions on biological
plausibility were similarly considered by the USEPA (2015) when
evaluating uncertainty in the doses used in the NTP study relative
to kinetic parameters as indicated by their following statement: “it
is possible that at lower exposures likely to be experienced by
humans, TBBPA would be excreted before it could exert adverse
effects.” (USEPA, 2015).
6. Discussion
Data demonstrate that TBBPA-induced uterine tumors occur via
a non-genotoxic MoA. Deﬁning the MIE for these tumors provides a
framework to determine the conditions by which this MoA would
be operative. The most plausible MIE, estrogen sulfotransferase
inhibition following high-dose repeated exposures, leads to a
disruption in estradiol metabolism. Subsequent key events include
an increase in estrogen bioavailability, an increase in estrogen-
related gene expression and cell proliferation, generation ofTable 7
Comparison of internal dosimetry following TBBPA exposure between animal and huma
Parameter
Animal
Plasma concentration at which saturation becomes limited in Wistar Han Ratsa
Human
Average maternal serum concentration in French womenb
95th percentile serum concentration in Belgian adolescentsc
Mean serum concentration reported in normal infants and their mothersd
a Plasma concentration following 28 days repeated exposure to 250 mg/kg oral dose (
b Non-detected samples do not appear to have been accounted for in derivation of av
c Median and 75th percentile values were below the limit of quantitation.
d Authors only reported lipid adjusted values; lipid levels were not reported and thusreactive quinones and subsequent DNA damage, and hyperplasia.
Data demonstrate that the adverse outcome occurs under the
conditions of chronic, high dose administration at a level sufﬁcient
to result in a prolonged increase in the bioavailability of estrogens
in uterine tissue in a strain of rat that appears to be sensitive to
development of uterine tumors.
Though not sufﬁcient to rule out the response for TBBPA, the
combined lack of historical control data, both for the Wistar Han
strain, and for the approach to evaluate the pathology, suggest the
need for caution in interpreting the ﬁndings, andmore importantly,
during extrapolation of plausibility and biological signiﬁcance to
humans. The data are particularly compelling when considering
that theMIE is only a consequence following administration of high
doses, and thus when considering human exposure levels (which
are orders of magnitude lower than doses associated with the MIE),
it is highly unlikely that the MIE, or subsequent key events, would
occur in humans. Human exposure levels are estimated to range
from 3.2 E7 to 8.4 E5 mg/kg-day, and lifetime average daily dose
estimates are associated with a margin of exposure that
is > 32,000,000 for cancer-based endpoints (Wikoff et al., 2015),
supporting that the AOP is not feasible in humans at current
exposure levels.
While a number of data gaps remain with respect to a robust
characterization of the relationship between the proposed MIE and
the AO (i.e., the development of uterine tumors), there is ample
evidence to support both (1) a MoA for uterine tumors associated
with an increased bioavailability of estrogens, and (2) modes of
action for non-genotoxic compounds that are only operative at high
doses in rodents (e.g., Golden et al., 1997). First, with respect to
MoAs associated with increased bioavailability of estrogens,
tamoxifen, a known ER agonist and antagonist, has been shown to
cause uterine tumors in both rats and humans (IARC, 2012). While
the MoA for tamoxifen is quite different than that hypothesized for
TBBPA, tamoxifen, unlike TBBPA, activates the ER, with speciﬁc
agonist activity in the endometrium, thus demonstrating it acts as
an estrogen by directly activating the ER rather than by disrupting
estrogen metabolism. No speciﬁc examples of compounds that
cause uterine tumors in humans or rats through a disruption in the
metabolism of estrogens leading to increased estrogen bioavail-
ability have been identiﬁed; however, there are examples of
environmentally-relevant compounds that have been shown to
interact with SULT1E1, the major estrogen sulfotransferase. For
example, many of the hydroxylated metabolites of polychlorinated
biphenyls (OH-PCBs) are potent inhibitors of SULT1E1 (Kester et al.,
2002). Researchers have postulated that exposure to PCBs may
cause endocrine disruption through SULT1E1 inhibition (Coughtrie
et al., 2002).
Second, it is well accepted that there are dose-dependent
changes in non-genotoxic modes of action that are operative only
at high doses. In a review by Slikker et al. (2004), the authors stated
that “It is highly likely that critical, limiting steps in any givenn datasets.
Concentration (nM) Citation
8662.4 Borghoff et al., 2016
0.290 Cariou et al., 2008
0.040 Kicinski et al., 2012
0.550 Kim and Oh, 2014
average of 4 and 8 h post administration).
erage by authors.
an average lipid content of 675 mg lipid/dl serum (Akins et al., 1989) was assumed.
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exposures, signaling the emergence of new modalities of toxic
tissue injury at these higher doses. Therefore, dose-dependent
transitions in principal mechanisms of toxicity may occur, and
could have signiﬁcant impact on the interpretation of reference
data sets for risk assessment.” In an analysis of NTP chronic bio-
assays, Gaylor (2005) reported that responses achieved from high
dose exposures to nongenotoxic compounds were likely to be
associated with a more universal mode of action, such as regener-
ative cell replication rather than due to a unique carcinogenic
property of a chemical.
Data presented in this evaluation demonstrate that such re-
sponses are likely to be occurring following chronic exposure to
high doses of TBBPA, such as those administered in the NTP (2014)
cancer bioassay. The recent investigation by Borghoff et al. (2016)
provides strong evidence that administration of high doses of
TBBPA results in a disruption in the bioavailability of estrogens via,
at least partly, a disruption in estrogen metabolism. The effects of
repeated, high-dose administration on its ability to saturate the
sulfate conjugation of TBBPA (~250 mg/kg-day in rodents) is
consistent with the proposed MIE that estrogen sulfation becomes
limited at high TBBPA dose levels. The correlation with levels of
TBBPA-S (used as a surrogate for representing estrogen sulfation
with TBBPA dose) is consistent with key events in the AOP, inwhich
the concentrations of TBBPA-S in the uterus correlates with the
incidence of atypical endometrial hyperplasia (AEH); both changes
plateau at doses of 250, 500 and 1000 mg/kg-day. And further,
statistically signiﬁcant increases in combined tumor types were
only observed in the 500 and 1000 mg/kg-day dose groups. Given
the evidence supporting that this event is a high-dose occurrence, it
is unlikely that such an event would occur in humans since the
TBBPA exposure levels in humans are up to eight orders of
magnitude lower (NTP, 2014; EU, 2006;Wikoff et al., 2015) than the
doses associated with saturation of these key enzymes in animal
studies.
Although evidence to date supports that the MIE is an inhibition
of estrogenic sulfotransferase by TBBPA, the potential role of the
inhibition of HSD17b warrants further research. If it were shown
that TBBPA could inhibit HSD17b activity in vivo, this inhibition
would further contribute to the increase in estradiol levels and
tissue bioavailability consistent with the proposed AOP. Addition-
ally, it is clear that both estrogen and TBBPA are metabolized in
tissues other than the uterus. Estrogen metabolism is better un-
derstood, with research showing estrogen metabolism mediated
through HSD17b enzymes, glucuronyltransferase, and sulfo-
transferase which occur in several tissues throughout the body,
including the liver (Rizner, 2013). The mechanism of TBBPA meta-
bolism throughout various tissues is less known; however, it is
clear that oxidative CYP-mediated phase I metabolism and phase II
conjugation via glucuronidation and sulfation of polybrominated
biphenyls occur throughout several tissues across humans and
animals, and thus further characterization of tissue-speciﬁc in-
creases, as well as increased circulating levels of estrogen also
warrant further investigation. The effects of TBBPA on the regula-
tion of local estrogen levels in the uterus will depend on a variety of
factors, such as the distribution of TBBPA to the uterus, its potency
for inhibiting sulfotransferases and/or glucuryltransferases, the
urinary or biliary excretion of its conjugates, and the reversal of
conjugation by local tissue levels of sulfatases or glucuronidases.
Some of the uncertainties in characterizing estrogen-mediated
events have to do with the challenge of measuring the actual
changes in estrogens and estrogen metabolites in the uterine tissue
as a result of limitation in the sensitivity of the analysis and vari-
ability in estrogen measurements to pick up a change. Thus,
rigorous research efforts would be required to fully evaluate thelevel of increased estrogens, as well as the duration of exposure,
necessary to generate a biologically meaningful change. Other data
gaps that, if ﬁlled, would improve the conﬁdence in the proposed
MoA include the following: 1) comparison of the inhibition of es-
trogen sulfation, 2) the role of glucuronidation in both human and
rat tissue following high dose TBBPA exposure, 3) characterization
of the relative contributions from the formation of reactive estro-
gen metabolites, 4) assessment of speciﬁc mutation frequency in
uterine tumors with dose of TBBPA, and 5) investigations to char-
acterize the likely strain-speciﬁc sensitivities of the Wistar Han rat
with respect to the development of spontaneous uterine tumors.
The MoA identiﬁed in this assessment has important implica-
tions for extrapolating the ﬁndings observed in rats to humans.
Data demonstrate that TBBPA-induced uterine tumors occur via a
non-genotoxic MoA, and suggest that tumors only occur at high
doses that disrupt homeostatic metabolic capabilities. As such, it
would be inappropriate to extrapolate cancer risk from high doses
to low doses with a model that presumes genotoxicity and a linear
doseeresponse relationship (Golden et al., 1997). Rather, a more
appropriate approach would involve extrapolation via a nonlinear
model, using a point of departure associated with a biologically
meaningful effect (e.g., saturation point, increased level of estrogen
in tissue). Or perhaps a different approach entirely, such as deri-
vation of a threshold of toxicological concern (TTC) (European
Commission, 2015); consistent with this approach, the metabolic
data in rodents suggest that at doses lower than ~250 mg/kg-day,
there is a negligible risk to humans as high doses (250 mg/kg-day
and above) are required to induce the MIE in a biologically mean-
ingful manner.
It is anticipated that the evidence discussed demonstrating that
the proposed MIE, binding and inhibition of estrogen sulfo-
transferases, as well as subsequent key events in the AOP for the
development of TBBPA induced uterine tumors, are events associ-
ated with high-dose, repeated exposures in a potentially sensitive
strain of rats. As such, the data presented in this assessment,
demonstrate that while the proposed AOP is potentially plausible in
humans, the MIE, as well as subsequent KEs, are not feasible in
humans based on differences in the kinetic and dynamic factors
between rats and humanswhen the current human exposure levels
of TBBPA are considered.
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